[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-cell-carcinoma-rcc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-cell-carcinoma-rcc":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,43,69,94,126,152,177,200,224,252,307,328,353,383,416,437,474,499,524,549,580,606,629,649,675],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100599643","phase-2-a-study-of-ibr854-combined-with-pazopanib-versus-pazopanib-in-advanced-renal-cell-carcinoma-100599643",false,"NCT07087158","A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Male or female, age ≥ 18 years old\n2. Advanced clear cell renal cell carcinoma confirmed by histology or cytology and not amenable to curative surgery.\n3. Has not received any previous systemic anti-tumor treatment for advanced renal cell carcinoma.\n4. Expected survival period is at least 3 months.\n5. ECOG performance status of 0 or 1, or KPS score of at least 70.\n6. Has measurable disease per RECIST 1.1.\n7. Organ function should meet the following criteria:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL; Platelet (PLT) ≥90×10\\^9\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL (no blood transfusion or hematopoietic stimulator treatment within 7 days).\n   2. Albumin ≥ 30 g\u002FL; Total bilirubin ≤1.5×ULN (for subjects with Gilbert's syndrome, it can be ≤3×ULN); ALT and AST ≤1.5×ULN (If liver metastasis is combined, ALT and AST≤3×ULN).\n   3. Creatinine (Cr) ≤1.5 × ULN; Creatinine clearance (Ccr) (to be calculated only when Cr \\> 1.5× ULN) \\> 50 ml\u002Fmin (Cockcroft-Gault formula).\n   4. Activated partial thrombin time (APTT) ≤1.5×ULN, International normalized ratio (INR) ≤1.5×ULN.\n8. Voluntarily sign the informed consent form, understand the study and be willing to follow the protocol and complete all experimental procedures.\n\nExclusion Criteria:\n\n1. Documented central nervous system metastases.\n2. Received prior antineoplastic therapy (including chemotherapy, biologic therapy, immunotherapy, or Chinese traditional medicines with antitumor indications) before the first dose of study treatment.\n3. Has received major surgery (grade 3 or 4 as defined in the Measures for the Administration of Clinical Application of Medical Technology) within 28 days before the first dose of study treatment and has not yet recovered from which; or any planned curative surgery for renal cell carcinoma during the study.\n4. History of another malignancy within 5 years before the first dose of study treatment, except for Lung carcinoma in situ, low-risk early-stage prostate cancer, or cured basal-cell carcinoma, squamous-cell carcinoma of the skin, cervical carcinoma in situ, or papillary thyroid carcinoma.\n5. Clinically significant gastrointestinal abnormalities such as malabsorption syndrome, major gastric or small-bowel resection that may affect drug absorption, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other conditions increasing the risk of perforation; or history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days before the first dose of study treatment.\n6. Systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) or other immunosuppressive agents required within 2 weeks before the first dose or anticipated during study treatment, except for:\n\n   1. Topical, intranasal, or inhaled corticosteroids.\n   2. Corticosteroids as premedication for infusion-related or hypersensitivity reactions (e.g., premedication for CT imaging).\n   3. Replacement therapy such as levothyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency.\n   4. Low-dose corticosteroids for orthostatic hypotension.\n7. Clinically significant cardiovascular or cerebrovascular disease documented by any of the following:\n\n   1. Ischemic stroke (excluding silent lacunar infarction) or severe thromboembolic event within 6 months before the first dose of study treatment.\n   2. Myocardial infarction, unstable angina, congestive heart failure, or clinically significant arrhythmia within 6 months before the first dose of study treatment.\n   3. New York Heart Association (NYHA) class ≥ II heart failure before the first dose of study treatment.\n   4. QTcF interval \\>450 ms (men) or \\>470 ms (women) before the first dose of study treatment.\n   5. Left-ventricular ejection fraction (LVEF) ≤50 % before the first dose of study treatment.\n8. Prior organ transplant, except corneal transplant; prior allogeneic stem-cell transplant.\n9. Hepatitis B surface antigen (HBsAg) positive with HBV DNA \\>500 IU\u002FmL or \\>2,500 copies\u002FmL, or hepatitis C antibody positive with detectable HCV RNA, or known HIV infection, or active tuberculosis.\n10. Interstitial lung disease or non-infectious pneumonitis that is currently symptomatic or has previously required systemic corticosteroids, in the opinion of the investigator likely to interfere with toxicity assessment or management.\n11. Any severe, progressive, or uncontrolled medical condition that, in the investigator's judgment, makes the subject unsuitable for the study, including but not limited to:\n\n    1. Infection requiring systemic therapy.\n    2. Symptomatic pleural, pericardial, or ascitic fluid requiring or having undergone drainage within 2 weeks before the first dose (minimal asymptomatic effusion, third-spacing due to hypoalbuminaemia, or cases where benefit outweighs risk may be allowed).\n    3. History of coagulopathy (e.g., deep-vein thrombosis) or severe bleeding diathesis; clinically significant bleeding event (e.g., gastrointestinal bleeding) within 1 month before the first dose.\n    4. History of severe psychiatric disorder.\n    5. Any other condition that, in the investigator's opinion, renders study participation riskier than beneficial.\n12. Prior grade 3-4 immune-related adverse events that, in the investigator's judgment, should be excluded.\n13. Severe allergic or hypersensitivity disorders, significant drug allergies (including to investigational agents), or known hypersensitivity to any component of the study drug, including severe reactions to monoclonal antibodies.\n14. Participation in another clinical trial and receipt of an investigational agent within 28 days before the first dose of study treatment.\n15. Clinically significant organ dysfunction or comorbidity likely to interfere with protocol adherence.\n16. Live vaccine received within 30 days before the first dose, or planned during the study or within 1 month after the last dose.\n17. Pregnant or breast-feeding women (women who agree to discontinue breast-feeding before signing informed consent may be enrolled).\n18. Any other condition or circumstance that, in the investigator's opinion, unsuitable for participation.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.",[27],"Renal Cell Carcinoma (RCC)",[29],"IBR854","RECRUITING","2026-07-01",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2025-09-08",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"Imbioray (Hangzhou) Biomedicine Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100566941","phase-3-testing-the-addition-of-the-anti-cancer-drug-tivozanib-to-immunotherapy-pembrolizumab-after-surgery-to-remove-all-known-sites-of-kidney-cancer-100566941","NCT06661720","Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer","Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE","STRIKE","Inclusion Criteria:\n\n* • Histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features following complete resection of the primary tumor (radical or partial nephrectomy)\n\n  * Note: Patients with microscopically positive soft tissue or vascular margins without gross residual disease are permitted\n\n    * Intermediate-high risk RCC:\n\n      * pT2 grade 4 or sarcomatoid features, N0M0\n      * pT3 any grade N0, M0\n    * High-risk RCC\n\n      * pT4, any grade, N0, M0\n      * pT, any stage., any grade, N+, M0\n    * cM1 no evidence of disease (NED) RCC\n\n      * Participants who have had resection of primary tumor (radical or partial nephrectomy) and resection or definitive radiation or ablation of solid, isolated, soft tissue metastases (excluding brain and bone lesions) at the time of primary tumor removal (synchronous) or ≤1 year from primary tumor removal (metachronous)\n\n        * Surgery (radical or partial nephrectomy or metastasectomy or ablation) \\> 4 weeks but =\\\u003C 16 weeks prior to study registration with no ongoing complications from surgery\n        * No evidence of disease at time of randomization as assessed by investigator by either CT or MRI scan of the brain and chest, abdomen and pelvis\n        * No prior systemic treatment for RCC\n        * Age \\>= 18 years\n        * Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (or Karnofsky \\>= 60%)\n        * Absolute neutrophil count (ANC) \\>= 1,000\u002Fmm\\^3\n        * Platelet count \\>= 100,000\u002Fmm\\^3\n        * Hemoglobin \\>= 8 g\u002FdL\n        * Total bilirubin =\\\u003C 3 x upper limit of normal (ULN)\n        * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 3 x upper limit of normal (ULN)\n        * Calculated (calc.) creatinine clearance \\>= 30 mL\u002Fmin (using Cockcroft Gault equation or the estimated glomerular filtration rate from the modification of diet in renal disease trial)\n        * Urine protein =\\\u003C 1+ on urine analysis (UA) or urine protein creatinine ration (UPCR) \\\u003C 2mg\u002Fmg\n        * Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test is required =\\\u003C 14 days prior to registration\n        * HIV status: HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n        * Hepatitis\n  * Hepatitis B: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with resolved HBV infection, defined as positive hepatitis B core antibody (anti-HBc) and negative hepatitis B surface antigen (HbsAg), are eligible\n  * Hepatitis C: Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n\n    * Cardiac Disease: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class IIB or better\n    * No history of myocarditis\n    * No history of clinically significant pneumonitis\n    * No uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 150 mm Hg or diastolic BP \\> 90 mm Hg) documented on 2 consecutive measurements taken at least 2 hours apart\n    * No serious non-healing wound, ulcer or bone fracture within 28 days prior to registration\n    * No serious\u002Factive infection requiring parenteral antibiotics\n    * No moderate or severe hepatic impairment (child-Pugh B or C)\n    * No significant bleeding disorders within 1 month prior to registration, for example:\n  * Hematemesis, hematochezia or other gastrointestinal bleeding grade 3 or higher\n  * Hemoptysis of pulmonary bleeding grade 3 or higher\n  * Hematuria or other genitourinary bleeding grade 3 or higher\n\n    * No history of allogeneic organ transplantation\n    * No history of allergy of hypersensitivity to study drugs or components\n    * No condition requiring systemic treatment with either corticosteroid (\\> 10 mg daily or prednisone equivalent) within 14 days of treatment initiation or other immunosuppressive medications within 30 days of randomization. Inhaled or topical steroids and adrenal replacement doses ≤10 mg daily prednisone equivalent are permitted in absence of active autoimmune disease\n    * No active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other gastrointestinal condition associated with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 4 weeks prior to registration\n    * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n    * No patients with a history of autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids \\> 10 mg\u002Fday, or immunosuppressive drugs) with the following exceptions:\n  * Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed\n  * Brief (\\\u003C7 days) use of systemic corticosteroids is allowed when use is considered standard of care\n  * Patients with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma\u002Fatopy will not be excluded\n  * Patients requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded\n  * Patients with hypothyroidism that is stable with hormone replacement or Sjögren's syndrome will not be excluded • Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment",{"count":52,"type":21},1040,[54],"PHASE3","This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.",[57,27,58,59],"Clear Cell Renal Cell Carcinoma","Stage II Renal Pelvis Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8",{"date":33,"type":34},{"date":62,"type":34},"2025-03-14",{"date":64,"type":21},"2037-11",{"name":66,"class":67},"Alliance for Clinical Trials in Oncology","OTHER",415,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":42},"100642612","phase-1-to-evaluate-the-safety-and-tolerability-of-anti-human-cd70-t-cell-injection-in-subjects-with-advancedmetastatic-renal-cancer-100642612","NCT07647744","To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced\u002FMetastatic Renal Cancer","A Phase I Clinical Study to Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced\u002FMetastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Age 18 to 70 years (inclusive), regardless of gender;\n2. Life expectancy of more than 12 weeks;\n3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1;\n4. Subjects with advanced\u002Fmetastatic renal cell carcinoma (RCC):\n\n   1. Histologically confirmed clear cell renal cell carcinoma (ccRCC), with an International Metastatic RCC Database Consortium (IMDC) risk stratification of intermediate or high risk as evaluated by the investigator;\n   2. Has at least one measurable lesion according to RECIST 1.1;\n   3. Tumor tissue samples must test positive for CD70 expression via immunohistochemistry (IHC);\n   4. Must have received at least one prior line of systemic therapy (must include at least: (1) immuno-oncology (IO) combination therapy: concomitant targeting of PD-1 and CTLA-4, or (2) an immune checkpoint inhibitor (PD-1\u002FPD-L1 inhibitor) combined with a VEGF\u002FVEGFR-targeted agent);\n5. Venous access required for apheresis can be established; hemoglobin ≥ 90 g\u002FL, absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL, and platelet count ≥ 100× 10\\^9\u002FL, and the leukepheresis can be carried according to the judgement of investigators;\n6. Hepatic, renal, cardiac, and pulmonary functions must meet the following criteria:\n\n   1. Creatinine clearance (CrCl) ≥ 50 mL\u002Fmin (calculated by the Cockcroft-Gault formula);\n   2. Left ventricular ejection fraction (LVEF) \\> 50%;\n   3. Baseline peripheral oxygen saturation \\> 95%;\n   4. Total bilirubin ≤2 × upper limit of normal (ULN);\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN;\n7. Voluntary participation in the clinical study: Must understand and be informed about this study, voluntarily sign the Informed Consent Form (ICF), and be willing to complete all study procedures.\n\nExclusion Criteria:\n\n1. Prior treatment with anti-CD70 targeted therapies;\n2. Brain metastasis from renal cell carcinoma;\n3. Concomitant with other uncontrolled malignancies, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or thyroid cancer after radical surgery;\n4. Any uncontrolled active infection, including but not limited to active tuberculosis; presence or suspicion of an uncontrolled infection, or an infection requiring systemic intravenous therapy within 14 days prior to enrollment (including fungal, bacterial, viral, or other infections);\n5. Subjects who are hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive, with peripheral blood HBV DNA titers above the lower limit of detection (LLOD) of the study site; those who are hepatitis C virus (HCV) antibody positive with peripheral blood HCV RNA positive; those who are human immunodeficiency virus (HIV) antibody positive; or those who test positive for syphilis;\n6. Any unstable systemic disease, including but not limited to: unstable angina, cerebrovascular accident or transient ischemic attack within 6 months prior to screening, myocardial infarction within 6 months prior to screening, congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ III ), poorly controlled diabetes mellitus (glycated hemoglobin HbA1c \\> 8% at screening), poorly controlled severe arrhythmia, and hepatic, renal, or metabolic diseases by medication;\n7. Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion (except for subjects of childbearing potential who are willing to use highly effective and reliable methods of contraception uninterruptedly for 1 year after the study treatment);\n8. Prior treatment with CAR-T therapy or other genetically modified cell therapies prior to screening;\n9. History of implantation of a cardiac pacemaker or deep brain stimulator;\n10. Vaccination with live attenuated vaccines within 4 weeks prior to leukapheresis;\n11. History of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) within the past 2 years that resulted in end-organ damage, or required systemic immunosuppressive therapy or other systemic disease-controlling medications;\n12. History of central nervous system (CNS) diseases, such as seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or psychiatric disorders; or known active CNS involvement or history thereof;\n13. Subjects who are receiving systemic steroid therapy prior to screening, and who are judged by the investigator to require long-term use of systemic steroids during the study treatment period (excluding inhaled or topical steroids);\n14. Presence of medical conditions that interfere with the ability to sign the written Informed Consent Form (ICF) or comply with study procedures; or those who are unwilling or unable to comply with study requirements;\n15. History of severe immediate hypersensitivity reactions to any of the medications to be used in this study;\n16. Any other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in this study.","70 Years",{"count":78,"type":21},18,[80],"PHASE1","This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in subjects with advanced\u002Fmetastatic renal cell carcinoma, and determine the recommended dose and infusion regimen for Phase 2 trials.",[27],[84,85,86],"Renal cell carcinoma","Chimeric antigen receptor","CD70","2026-06-30",{"date":33,"type":34},{"date":87,"type":34},{"date":91,"type":21},"2034-06",{"name":93,"class":41},"Hrain Biotechnology Co., Ltd.",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100452820","phase-1-study-of-zanzalintinib-in-combination-with-immuno-oncology-agents-in-participants-with-solid-tumors-100452820","NCT05176483","Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors","STELLAR-002","Key Inclusion Criteria:\n\n* Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic.\n* Dose-Escalation Cohorts: Participants with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.\n* Expansion Cohort 1 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component who have not received prior systemic therapy.\n\n  * Note: Prior non-vascular endothelial growth factor (VEGF) targeted adjuvant or neoadjuvant is allowed if disease recurrence occurred 6 months after the last dose.\n* Expansion Cohort 2 (ccRCC): Participants with unresectable advanced or metastatic RCC with a clear cell component.\n\n  * Must have radiographically progressed after a combination therapy consisting of a Programmed Cell Death Protein 1 (PD-1)\u002FProgrammed death-ligand 1 (PD-L1) targeting monoclonal antibody (mAb) with a Vascular endothelial growth factor (receptor) tyrosine kinase inhibitor (VEGFR-TKI) or a PD-1 targeting mAb with a CTLA-4 mAb as the preceding line of therapy.\n  * Must have received no more than one prior systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma.\n* Expansion Cohort 3 (mCRPC): Men with metastatic adenocarcinoma of the prostate.\n\n  * Must have progressed during or after one novel hormone therapy (NHT) given for castration-sensitive locally advanced (T3 or T4) or metastatic castration-sensitive prostate cancer (CSPC), M0 CRPC, or mCRPC.\n* Expansion Cohort 4 (UC, ICI-naive): Participants with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra).\n\n  * Must have progressed during or after prior first-line platinum-based combination therapy, including participants who received prior neoadjuvant or adjuvant platinum-containing therapy with disease recurrence \\\u003C 12 months from the end of last therapy.\n  * Must have received no more than 1 prior line of systemic anticancer therapy for unresectable, locally advanced or metastatic disease.\n* Expansion Cohort 5 (post enfortumab vedotin \\[EV\\] and ICI): Participants with histologically confirmed unresectable, locally advanced or metastatic predominant urothelial carcinoma.\n\n  * Progressive disease following prior EV or ineligible for EV, and progression following prior PD-1\u002FPD-L1 inhibitor or ineligible for PD-1\u002FPD-L1 inhibitor.\n  * Prior receipt of platinum-based therapy allowed but not required.\n  * Prior therapy with other agents allowed but not required.\n* Expansion Cohort 6 (nccRCC): Participants with unresectable advanced or metastatic nccRCC of the following subtypes: Papillary, unclassified RCC, and translocation-associated, Fumarate Hydratase (FH) deficient and Succinate Dehydrogenase (SDH) deficient. Among the eligible histologic subtypes, sarcomatoid features are allowed.\n\n  * No prior systemic anticancer therapy is allowed except adjuvant or neoadjuvant therapy if disease recurrence occurred at least 6 months after the last dose.\n* Expansion Cohort 7 (HCC): Participants with locally advanced, or metastatic and\u002For unresectable HCC that is not amenable to curative treatment or locoregional therapy.\n* Expansion Cohort 8 (NSCLC): Participants with Stage IV non-squamous NSCLC with positive PD-L1 expression (tumor proportion score \\[TPS\\] 1-49%) and without prior systemic anticancer therapy for metastatic disease.\n* Expansion Cohort 9 (NSCLC): Participants with Stage IV non-squamous NSCLC who have radiologically progressed following treatment with one prior immune checkpoint inhibitor (anti-PD-1 or anti-PD-L1) for metastatic disease.\n* Expansion Cohort 10 (CRC): Participants with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum.\n* Expansion Cohort 11 (HNSCC): Participant with inoperable, refractory, recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx. PD-L1 combined positive score (CPS) ≥1.\n* Expansion Cohort 12 (ccRCC): Participants with unresectable advance or metastatic RCC with a clear cell component, including participants who also have a sacromatoid feature.\n\n  * Must have received no more than two prior lines of systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma\n* Expansion Cohort 13 and Cohort 14 (ccRCC 1L): Participants with unresectable advanced or metastatic RCC with a clear component, including participants who also have a sacromatoid feature.\n* For all Expansion Cohorts except Cohort 3: Measurable disease per RECIST 1.1 as determined by the Investigator.\n* For Expansion Cohorts 1 - 11 Only: Archival tumor tissue material, if available, or fresh tumor tissue if it can be safely obtained.\n* Recovery to baseline or ≤ Grade 1 common terminology criteria for adverse events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and\u002For stable on supportive therapy.\n* Karnofsky Performance Status (KPS) ≥ 70%.\n* Adequate organ and marrow function.\n* Sexually active fertile participants and their partners must agree to use highly effective methods of contraception.\n* Females of childbearing potential must not be pregnant at screening.\n\nKey Exclusion Criteria:\n\n* For all Dose-Escalation cohorts: Prior treatment with zanzalintinib. For all Expansion Cohorts: Prior treatment with zanzalintinib, nivolumab, ipilimumab or relatlimab with the following exceptions: Prior PD-1\u002FPD-L1, Lymphocyte-activation gene 3 (LAG-3) and cCytotoxic T lymphocyte associated protein 4 (CTLA-4) targeting therapy for locally advanced or metastatic disease is allowed for Cohort 2 (ccRCC), Cohort 5 (UC), Cohort 9 (NSCLC), and Cohort 12 (ccRCC), and prior treatment in the neoadjuvant or adjuvant setting is allowed for Cohort 13 and Cohort 14 (ccRCC 1L).\n* For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC), Cohort 10 (CRC), and Cohort 12: Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n* For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment.\n* For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC) and Cohort 10 (CRC), and Cohort 12: Receipt of any type of anticancer antibody or systemic chemotherapy within 4 weeks before first dose of study treatment.\n* Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.\n* Prior external radiation therapy for bone metastasis within 2 weeks, for other tumor sites within 4 weeks, and prior radium-223 therapy within 6 weeks before first dose of study treatment, unless otherwise specified.\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.\n* Concomitant anticoagulation with oral anticoagulants, except for specified direct factor Xa inhibitors.\n* Administration of a live, attenuated vaccine within 30 days prior to first dose.\n* Uncontrolled, significant intercurrent or recent illness.\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 460 ms for females and \\> 450 ms for males per electrocardiogram (ECG) within 14 days before first dose of study treatment.\n* Participants with inadequately treated adrenal insufficiency.\n* Pregnant or lactating females.\n* Any other active malignancy within two years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.\n* For Cohort 2 (ccRCC, 2L): Receipt of a prior triplet therapy including a VEGFR-TKI, a PD1 targeting mAb, and a CTLA-4 mAb.\n* For Cohort 3 (mCRPC): Receipt of a taxane-based chemotherapy for mCRPC.\n* For Cohort 4 (UC, ICI-naïve): Participants who have had recurrence within the 6 months of completing adjuvant anti-PD-(L)1 treatment.\n* For Cohort 6 (nccRCC, 1L): Participants with chromophobe, renal medullary carcinoma, or pure collecting duct nccRCC.\n* For Cohort 7 (HCC):\n\n  * Documented hepatic encephalopathy (HE) within 6 months before the first dose.\n  * Clinically meaningful ascites (ie, ascites requiring paracentesis or escalation in diuretics) within 6 months before randomization.\n  * Participants who have received any local anticancer therapy including surgery, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave ablation (MWA), transarterial chemoembolization (TACE), or transarterial radioembolization (TARE) within 28 days prior to first dose.\n  * Participants with known fibrolamellar carcinoma, sarcomatoid HCC, or mixed hepatocellular cholangiocarcinoma\n* For Cohort 10 (CRC, 2L+): Receipt of prior therapy with regorafenib and\u002For trifluridine + tipiracil (TAS-102).\n* For Cohort 11 (HNSCC): Primary tumor site of the nasopharyngeal area.\n* For Cohorts 1 (ccRCC, 1L), 2 (ccRCC, 2L), 4, 5 (UC), 7 (HCC), 8 (NSCLC 1L PD-L1 low), 9 (NSCLC, 2L+), 10 (CRC, microsatellite stable \\[MSS\\], 2L+), and 11 (HNSCC):\n\n  * Troponin T (TnT) or I (TnI) \\> 2 × institutional upper limit of normal (ULN).\n\nNote: Additional Inclusion and Exclusion criteria may apply.",{"count":103,"type":21},1314,[80],"This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.\n\nIn the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.",[27,107,108,109,110,111,112,113,114,115],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Urothelial Carcinoma (UC)","Solid Tumor","Hepatocellular Carcinoma (HCC)","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Non-Clear Cell Renal Cell Carcinoma (nccRCC)","2026-06-17",{"date":118,"type":34},"2026-06-22",{"date":120,"type":34},"2021-12-14",{"date":122,"type":21},"2030-06-28",{"name":124,"class":41},"Exelixis",122,{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":42},"100641290","phase-1-a-phase-1-and-2-study-of-vmd-102-in-hepatocellular-carcinoma-and-other-solid-tumors-100641290","NCT07636785","A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors","SPKTAHC","Inclusion Criteria:\n\n* Histological or cytological or radiological diagnosis of advanced (unresectable and\u002For metastatic) HCC, MUM, RCC, NSCLC and CRC that is not responsive to standard of care (SOC), had progressed following SOC, is intolerant to SOC, or for whom the SOC is not considered appropriate by the investigator.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, or 1.\n* Has at least one measurable target lesion according to RECIST v1.1 \\[Response Evaluation Criteria In Solid Tumors\\], or mRECIST \\[modified RECIST\\] for unresectable HCC participants, and either (a). has not been previously treated with local therapy (e.g., radiation therapy, hepatic arterial embolization, radiofrequency ablation, and percutaneous interventional therapy), or (b). if the target lesion was within the field of local therapy, the lesion has shown an increase in size of 25% or greater following local therapy.\n* Adequate organ function evidenced by:\n\nHematology\n\n* Hemoglobin ≥ 9 g\u002FdL (SI Units: 90 g\u002FL) (post-transfusion if transfusion-dependent)\n* Platelet count ≥ 60000\u002Fmm3 (60 x109\u002FL) without support(transfusion) within 7 days of testing\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm3 (1.5x109\u002FL) Chemistry\n* Total bilirubin (TBIL) ≤ 2.0 x upper limit of normal (ULN). (For participants with Gilbert's syndrome, TBIL ≤3.0 x ULN provided that direct bilirubin DBIL) is \\\u003C30% of the TBIL)\n* Aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) 1 ≤ 5 x U LN (participants with advanced HCC or liver metastases)\n* AST and\u002For ALT 1 ≤ 3 x ULN (participants without known liver disease or liver metastases)\n* Calculated creatinine clearance or 24h urine creatinine clearance ≥50 mL\u002Fmin using Cockroft-Gault formula.\n* Serum creatinine ≤ 1.5x ULN\n\nCoagulation (unless taking an anti-coagulant):\n\n* Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (except for participants receiving therapeutic anticoagulants)\n* International normalized ratio (INR) ≤ 1.5 unless the participant is receiving anticoagulant therapy as long as the participant is within therapeutic range of intended use of anticoagulants\n* Albumin ≥2.8g\u002Fd\u002FL.\n\n  * For HCC participants: the diagnosis must be made based on American Association for the Study of Liver Diseases (AASLD) Guidelines with confirmed advanced (unresectable) HCC staged by Barcelona Clinic Liver cancer criteria (BCLC). Cirrhosis will be staged by Child-Pugh score, and such a score ≤ 6 will be eligible for Phase 1 and ≤7 for Phase 2.\n  * Participants must either have available archival tumor tissue samples, or consent to fresh tumor tissue sampling prior to the first dose unless the biopsy is not safe or not feasible per investigator assessment and with medical monitor approval.\n  * Women of childbearing potential (WOCBP) must have a negative pregnancy test prior to enrolment and agree to use a highly effective and acceptable method of contraception from the time of informed consent (or screening) until 6 months after the last dose of investigational agent.\n  * Male participants who are sexually active with a female partner of childbearing potential must agree to use a condom with spermicide from first dose of investigational agent until 6 months after the last dose, and refrain from sperm donation during that period. Abstinence from heterosexual intercourse is an acceptable method only if the participant's usual lifestyle already includes abstinence.\n  * Participant has a life expectancy of ≥3 months.\n  * No history of liver transplantation.\n  * Ability to swallow and absorb an orally self-administered medication in tablet form.\n  * Have completed any prior chemotherapy, monoclonal antibody or immunotherapy (e.g., tumor vaccine, cytokine, or growth factor given to control the cancer) at least 4 weeks or 5 half-lives (whichever is shorter) before study drug administration. Exceptions to these prior therapy timeframes are possible, on a case by case basis, following discussion and mutual agreement between Investigator and Sponsor.\n  * Adverse effects related to prior anticancer therapies must have either returned to baseline or resolved to Grade 0 or 1. Some toxicities with higher grades such as alopecia, immunotherapy-induced hypothyroidism or adrenal insufficiency or panhypopituitarism requiring stable doses of hormone replacement therapy or rash from prior therapy may be permitted with medical monitor approval.\n\nExclusion Criteria:\n\n* Received anticancer therapy with radiation, immunotherapy, a biologic, surgery and\u002For tumor embolization within the past 2 weeks or 5 half-lives (whichever is longer).\n* Currently pregnant, nursing, or planning to become pregnant during the course of study.\n* The Fridericia Corrected QT (QTcF) interval ≥ 480 msec.\n* Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system (Section 14.8); or presence of clinically significant and uncontrolled cardiac disease, as assessed by the investigator. Such as but not limited to: symptomatic congestive heart failure, unstable angina, cardiac arrhythmia.\n* Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the participant's safety or interfere with assessment of the drug.\n* Psychological, familial, sociological, geographical or other concurrent conditions that would interfere with safety evaluation, limit the participant's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Participants with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded.\n* Participants have multiple factors that affect their oral medication (such as inability to swallow and intestinal obstruction or resection).\n* Participants have long-term unhealed wounds or fractures.\n* Participants have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage.\n* Any current medical conditions, including impairment of GI function or GI disease, which would alter the absorption, distribution, metabolism or excretion of VMD-102 including but not limited to:\n\n  * Severe uncontrolled nausea or vomiting.\n  * Severe uncontrolled diarrhea or ongoing active diarrhea requires medications (e.g. bile acid sequestrant, loperamide).\n  * A history of short bowel syndrome; irritable bowel syndrome with diarrheal signs\u002Fsymptoms or require medications.\n  * Clinically diagnosed malabsorption secondary to bowel resection.\n  * Active Ulcerative colitis or Crohn's disease requiring medication for control.\n  * Surgical procedures of the GI tract impacting the drug absorption such as but not limited to small bowel resection and gastric bypass.\n* Unstable central nervous system (CNS) metastases. Participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least one cycle prior to the first dose and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are on stable doses of steroids for at least one cycle prior to the first dose.\n* Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC or HCC due to cirrhosis caused from autoimmune-associated hepatitis.\n* Hepatitis B surface antigen (HBsAg) positive with detectable the hepatitis B virus load (HBV DNA) \\>100 IU\u002FmL. Participants on active HBV therapy with viral loads \\\u003C100 IU\u002FmL should stay on the same therapy throughout study intervention and at least 12 weeks after the study is over. Participants cannot be actively co-infected with hepatitis C virus (HCV; HCV RNA detectable) or hepatitis delta virus (HDV; HDV RNA detectable).\n* Positive HBsAg, with or without detectable HBV DNA, if there is evidence in the medical history of an advanced stage of cirrhosis ( Child-Pugh B) or history of decompensated chronic liver disease\n* HCV antibody (HCVAb) positive and HCV viral load (HCV RNA) detectable. Previous HCVAb positive with HCV RNA undetectable due to treatment (DAAs or interferon) is allowed but the treated participants must have completed their treatment at least 12 weeks prior to starting study intervention and HCV RNA must be documented at below the limit of quantification.\n* History of allogeneic tissue\u002Forgan transplantation (including bone marrow, stem cell, liver, or kidney transplants), except those that do not require immunosuppressive therapy (e.g., corneal or hair transplants).\n* Coronavirus disease 2019 (COVID-19) or any live attenuated vaccine within 4 weeks of study entry.\n* Participants with active alcohol and\u002For substances abuse, Phosphatidylethanol (Peth) must be \\\u003C50 ng\u002FmL).\n* Concurrent secondary malignancy other than that being treated in this study. Exceptions to this exclusion include malignancies treated curatively and have not recurred within 2 years prior to study entry or tumors treated with curative intent that have expected cure rates of \\>90% such as but not limited to: basal cell and squamous skin cancer and completely resected carcinoma in situs.\n* Participants have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage. Exception may be possible, on a case by case basis, e.g. if no more than one paracentesis in a month and a drain is pre-placed for the participant to drain, following discussion and mutual agreement between Investigator and Sponsor\n* Participants have long-term unhealed wounds or fractures.\n* Participants receiving known potent P-glycoprotein (P-gp) efflux transporter inhibitors that cannot be discontinued 3 days prior to the start of study treatment and during the course of the Phase 1 study.\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drug, or excipients.\n* Known history of uncontrolled human immunodeficiency virus (HIV) infection.\n* Any other condition that, in the opinion of the Investigator or the medical monitor, could increase the risk to the participant, interfere with study participation, or affect the proper interpretation of study results and objectives. Such conditions may include but are not limited to, active infections, uncontrolled diabetes, psychiatric illness, social situations, and concomitant therapies.","75 Years",{"count":136,"type":21},111,[80,24],"This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed.\n\nVMD-102 will be the first selective PKC epsilon (PKCε or PKCe) kinase inhibitor to enter human clinical testing. Preclinical VMD-102 anti-tumor activities in mouse liver\u002FHCC tumor models and preclinical toxicology and pharmacology studies support this study.",[110,140,27,141,112],"Metastatic Uveal Melanoma","Nonsmall Cell Lung Cancer","NOT_YET_RECRUITING","2026-06-16",{"date":145,"type":34},"2026-06-18",{"date":147,"type":21},"2026-06",{"date":149,"type":21},"2031-12",{"name":151,"class":41},"VM Discovery, Inc.",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":161,"phases":4,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":42},"100641093","study-on-mrd-prediction-of-efficacy-of-toripalimab-in-the-treatment-of-high-risk-recurrent-renal-carcinoma-100641093","NCT07657325","Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma","Predictive Value of Minimal Residual Disease for Efficacy of Toripalimab in High-risk Recurrent Renal Cell Carcinoma Following Nephrectomy: A Prospective Single-arm Study","1. There must be a histological diagnosis of renal cell carcinoma, with or without sarcomatoid features of clear cell components.\n2. On the day of signing the informed consent form, both males and females must be at least 18 years old.\n3. The participants provide written informed consent for the trial before enrollment.\n4. Have high risk or M1 NED renal cell carcinoma as defined by the following pathological tumor-node-metastasis and Fuhrman grading status.\n\n   1. High risk RCC\n\n      * pT4, Any Gr. N0, M0\n      * pT Any stage, Any Gr., N+, M0\n   2. M1 NED RCC (participants who present not only with the primary kidney tumor but also solid, isolated, soft tissue metastases that can be completely resected at the time of nephrectomy)\n5. No previous systemic treatment for advanced RCC (except nephrectomy or pyelectomy) has been performed.\n6. Radical nephrectomy (and complete resection of metastatic lesions in M1 NED participants) was performed with a negative surgical margin.\n7. It must be evaluated by the investigator as tumor-free and verified by imaging such as CT or MRI. No suspicious brain metastases.\n8. Have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n9. Non-surgical sterilization or female participants of childbearing potential who are required to use a medically approved contraceptive method (such as an IUD, contraceptive pill or condom) during the study treatment period and for 3 months after the end of the study treatment period; Serum or urine HCG tests must be negative for women of non-surgical sterilization or childbearing age within 7 days prior to study enrollment; And must be non-lactation period; Non-surgical sterilization or male patients of childbearing age who consent to use a medically approved contraceptive method with their spouse during the study treatment period and for 3 months after the end of the study treatment period.\n10. Vital organ function meets the following requirements (excluding use of any blood components and cell growth factors within 14 days) : normal bone marrow reserve function; Absolute neutrophil count (ANC)≥1500\u002FµL, Platelets≥100 000\u002FµL, Hemoglobin ≥5.6 mmol\u002FL (9g\u002FdL); Normal renal function or serum creatinine ≤1.5 mg\u002Fd and\u002For creatinine clearance ≥30 mL\u002Fmin for participants with creatinine levels \\>1.5×institutional ULN; Normal liver function or Total bilirubin ≤1.5xULN, or direct bilirubin≤ULN for participants with total bilirubin levels \\>1.5×ULN; AST (SGOT) and ALT (SGPT) ≤2.5×ULN; International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN.",{"count":160,"type":21},110,"OBSERVATIONAL","This is a prospective cohort study aimed at clarifying the predictive value of MRD for postoperative DFS and OS in high-risk recurrent renal cell carcinoma patients who have undergone radical nephrectomy and received adjuvant treatment with Toripalimab. Further differentiating patients who need adjuvant immunotherapy.",[27],[165,166,167,168],"Minimal Residual Disease","Toripalimab","Renal Cell Carcinoma","Disease Free Survival","2026-06-15",{"date":145,"type":34},{"date":172,"type":34},"2024-04-01",{"date":174,"type":21},"2028-02-01",{"name":176,"class":67},"Tianjin Medical University Second Hospital",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":42},"100595921","investigation-of-lymph-node-biology-in-kidney-cancer-100595921","NCT07038733","Investigation of Lymph Node Biology in Kidney Cancer","Characterizing the Tumor-draining Lymph Nodes and Other Immune Sites in Renal Cell Carcinoma","LN-RCC","Inclusion Criteria:\n\nCandidates for inclusion include adult patients with either a known or suspected kidney cancer referred to Yale Genitourinary Oncology providers in the Yale Urology, Medical Oncology and Radiation Oncology or Nephrology Departments. These individuals will be receiving clinical evaluation\u002Fmedical treatment\u002Fsurgery\u002Fprocedures at Yale New Haven Hospital or the Smilow Cancer Hospital.\n\nParticipant eligibility will be determined by study investigators and will be offered protocol details. Interested participants will be invited to participate by study investigators. Consent will be obtained by study investigators or other authorized study personnel. Any potential adult participants with known or suspected kidney cancers with a renal mass who are patients of non-study physicians will be invited to participate by study personal only with the approval of their treating physician.\n\nExclusion Criteria\n\n* Participants under the age of 18. Children will not be enrolled on the study.\n* Participants known to be pregnant or actively breastfeeding.\n* Iodine allergy hypersensitivity.",true,{"count":187,"type":21},33,[189],"NA","The purpose of this pilot study is to investigate the phenotype, anti-tumor effector functions, and TCR repertoire of T cells isolated from patient tumor draining lymph nodes (TDLNs) to understand T cell priming and trafficking patterns in Renal Cell Carcinoma (RCC). Data and biospecimen collected will be used for current and future research projects involving the study of kidney cancer biology and related medical conditions. Investigators will use this valuable resource to ask clinically relevant translational questions that pertain to biomarker discovery\u002Fvalidation, identification of novel therapeutic targets, and to better understand the genetic and biological basis of the various kidney cancers.",[27],"2026-06-12",{"date":143,"type":34},{"date":195,"type":34},"2026-01-30",{"date":197,"type":21},"2030-12",{"name":199,"class":67},"Yale University",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100625223","phase-1-a-phase-1-study-of-the-safety-and-tolerability-of-ctx-10726-100625223","NCT07419841","A Phase 1 Study of the Safety and Tolerability of CTX-10726","A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Patients must have a histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic disease that is relapsed\u002Frefractory to standard therapy or for which no effective standard therapy is available, including:\n\n2a: Renal Cell Carcinoma (RCC)\n\n* Histologically confirmed diagnosis of renal cell carcinoma (with clear cell component) with advanced or metastatic disease that is not amenable to cure by surgery or other means.\n* Patients who have progressed after a minimum of 2 doses of a programmed cell death 1 (PD-1)\u002F programmed cell death ligand 1 (PDL1) treatment.\n* Patients must have received at least one regimen including a tyrosine kinase inhibitor (TKI).\n* Patients who received immunomodulatory drugs (thymosin, interferon, interleukin, etc.) within 2 weeks before the first dose or received major surgical treatment within 3 weeks before the first dose are not eligible.\n\n  2b: Hepatocellular Carcinoma (HCC)\n* Patients who have progressed after a minimum of 2 doses of a PD-1\u002FPDL1 treatment.\n* Patient must have received one of the following regimens: ipilimumab+nivolumab, tremelimumab+durvalumab, atezolizumab+bevacizumab or lenvatinib+pembrolizumab.\n* Hepatic function: Child -Pugh A and Child-Pugh B7.\n* Receipt of local area treatment of the liver more than 4 weeks prior to the first dose is allowed.\n\n  2c. Gastroesophageal Cancer (GC)\n* Patients who have progressed after a minimum of 2 doses of a PD-1\u002FPDL1 treatment.\n* Patients must have received prior treatment with platinum-based chemotherapy.\n\n  2d: Endometrial Cancer (EC)\n* Patients must have received at least 1 cycle of platinum-based chemotherapy.\n* Patients with newly diagnosed advanced endometrial cancer that have persistent lesion(s) after standard treatment with surgery and chemotherapy ± radiotherapy.\n* Patients with MSI- high or deficient DNA mismatch repair (dMMR) tumors who have progressed after a minimum of 2 doses of a PD-1\u002FPDL1 treatment.\n\n  3\\. Patients must have measurable disease per RECIST 1.1. Tumor sites that are considered measurable must not have received prior radiation.\n\n  4\\. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n\n  5\\. Adequate organ function including:\n* Bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109\u002FL, platelet count of ≥ 100.0×109\u002FL, and hemoglobin of ≥ 9.0 g\u002FdL (with or without transfusion).\n* Hepatic function defined as serum total bilirubin ≤ 1.5 × ULN (\\\u003C3 x ULN in patients with Gilbert's syndrome), AST\u002FALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases).\n* Renal function defined as creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft Gault equation.\n* Cardiac function with Left Ventricular Ejection Fraction (LVEF) ≥ 50%.\n\n  6\\. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives) or abstinence for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment.\n\n  7\\. Female patients who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening within 7 days of dosing with CTX-10726.\n\n  8\\. Prior anticancer therapy \\> 28 days (or 2 half-lives for proteins, whichever is shorter), radiotherapy \\> 7 days (concurrent localized palliative radiotherapy is allowed during CTX-10726 treatment with medical monitor approval), therapeutic surgical intervention \\> 21 days, blood transfusion \\> 14 days, or biopsy or minor surgery (excluding placement of vascular access devices) \\> 7 days prior to the first dose of CTX-10726.\n\n  9\\. Resolution of all prior anti-cancer therapy toxicities ≤ Grade 2 (excluding alopecia).\n\n  10\\. Capable of understanding and complying with protocol requirements\n\n  11\\. Signed and dated institutional review board (IRB) approved informed consent form (ICF) before any protocol-directed screening procedures are performed.\n\nExclusion Criteria:\n\n1. Developed clinically significant adverse reaction to prior PD-1 or PD-L1 therapy, including immune related adverse reactions (irAE), that led to discontinuation of treatment. A prior irAE may be considered not exclusionary only after consultation with the Medical Monitor if it resolved or stabilized to Grade 1 or baseline before informed consent, has been clinically stable for at least 3 months, and does not require ongoing systemic corticosteroids or other systemic immunosuppressive therapy other than protocol-permitted physiologic replacement. Participants are not eligible if the prior irAE was severe or life-threatening, involved a high-risk organ system with potentially dangerous recurrence, was recurrent or occurred after rechallenge, required second-line immunosuppressive therapy beyond corticosteroids, suggested broad immune susceptibility, or could confound safety evaluation in this first-in-human study.\n2. Prior organ transplantation.\n3. History of arterial or venous thrombosis or stroke or transient ischemic attack within 6 months prior to the first dose.\n4. History of other neoplasms within 3 years prior to screening, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that has undergone successful surgery.\n5. Symptomatic or uncontrolled central nervous system (CNS) and brain metastasis or active leptomeningeal disease. Patients with equivocal findings or with confirmed brain metastases are eligible for the study provided that they are asymptomatic and radiologically and neurologically stable without the need for corticosteroid treatment or seizure prophylaxis for \\>4 weeks before the first dose of study drug. Prior treatment with either surgery or radiation is permitted and all patients with a history of CNS or brain lesions require imaging during screening to confirm stability.\n6. A pleural, abdominal (eg, ascites) or pericardial effusion that is clinically symptomatic or requires repeated management (puncture or drainage, etc) within 14 days of dosing with CTX-10726.\n7. Imaging at screening that shows the tumor surrounds important blood vessels or had obvious necrosis and voids, and the investigators deems that it might cause bleeding risk.\n8. The presence of severe, unhealed or open wounds, active ulcers, or untreated fractures at the time of screening.\n9. A history of significant bleeding tendency or severe coagulopathy.\n10. Current therapeutic dose of anticoagulant or thrombolytic medication within 14 days of the first dose. Note: prophylactic use of low molecular heparin (ie, enoxaparin 40 mg\u002Fday) is allowed.\n11. Current or recent use of aspirin (\\> 325 mg\u002Fday) or other non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days of first dose.\n12. Known uncontrolled diabetes mellitus despite optimized anti-diabetes medications.\n13. The presence of poorly controlled hypertension (systolic blood pressure \\[SBP\\]\u002Fdiastolic blood pressure \\[DBP\\]) \\>140\u002F90 mmHg (eg, patient with SBP\u002FDBP \\> 140\u002F90 mmHg despite ≥3 anti-hypertensive medications within 7 days of dosing with CTX-10726).\n14. Pregnant or lactating WOCBP.\n15. Patients with evidence of active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. Patients with positive HBsAg and\u002For detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.\n\n    1. Hepatitis B subjects who meet the following criteria are also eligible for inclusion: HBV viral load must be \\\u003C 1000 copies \u002Fml (200 IU\u002Fml) prior to initial dosing, and subjects should receive anti-HBV therapy to avoid viral reactivation throughout the duration of study chemotherapy drug treatment. For subjects with anti-HBC (+), HBsAg (-), anti-HBS (-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring of viral reactivation is required.\n    2. HIV-infected subjects who meet the following criteria are eligible for inclusion: HIV-RNA levels below the lower limit of detection.\n16. Active HCV-infected subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection).\n17. Patients that received attenuated vaccination within 4 weeks prior to screening or planning to receive attenuated vaccination during the study period.\n18. Current or recent systemic therapy with immunosuppressive agents within 7 days before the start of CTX-10726 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement (≤ 10 mg\u002Fday prednisone or equivalent) for patients with adrenal insufficiency are allowed.\n19. Active autoimmune disease or medical conditions requiring chronic steroid (i.e., \\> 10 mg\u002Fday prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor.\n20. Active or prior documented idiopathic pulmonary fibrosis or idiopathic pneumonia; current acute lung disease, interstitial lung disease or pneumonia (except localized interstitial pneumonia due to radiotherapy induction), pulmonary fibrosis, severe respiratory distress, pulmonary insufficiency or continuous oxygenation.\n21. Other medical conditions in the opinion of the Investigator and\u002For Sponsor Medical Monitor may interfere with the conduct and\u002For interpretation of the current study, including:\n\n    1. Congestive heart failure (\\> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias.\n    2. QTc interval (using Fridericia correction calculation) \\> 480 msec.",{"count":208,"type":21},70,[80],"This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.",[212,110,213,27],"Gastroesophageal Cancer (GC)","Endometrial Cancer","2026-06-04",{"date":216,"type":34},"2026-06-05",{"date":218,"type":34},"2026-05-28",{"date":220,"type":21},"2028-11-01",{"name":222,"class":41},"Compass Therapeutics",5,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":42},"100571634","clampless-sutureless-partial-nephrectomy-for-renal-masses-100571634","NCT06722807","ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses","ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses (CASPIAN)","CASPIAN","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Patients undergoing partial nephrectomy for renal masses ≤ 7 cm\n* Subjects must not have more than one active malignancy at the time of enrollment. (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \\[as determined by the treating physician or approved by the Principal Investigator\\] may be included).\n* A clinical diagnosis consistent with renal cell carcinoma, cT1-3 N0 M0 without renal vein thrombus.\n* Adequate laboratory test results, including:\n\n  1. Platelets \\> 50,000\u002FµL\n  2. Hemoglobin \\> 9.0 g\u002FdL\n* Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.\n* Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 2 weeks after surgery to minimize the risk of pregnancy. Prior to study enrollment, subjects of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.\n* Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 2 weeks following surgery.\n\nExclusion Criteria:\n\n* Bleeding disorder (any congenital bleeding diathesis)\n* Liver dysfunction with end stage liver disease as determined by the treating investigator\n* Presence of renal vein thrombus\n* End stage renal disease (eGFR \\\u003C 15 using Cockcroft-gault formula or receiving renal replacement therapy (i.e. dialysis))\n* Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 2 weeks after surgery.\n* Subjects who are confirmed to be pregnant or breastfeeding.\n* History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.\n* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.",{"count":233,"type":21},59,[189],"During partial nephrectomy surgery, efforts at minimizing ischemia while maximizing renal parenchymal volume are desirable to preserve renal function1,2. Not only clamping of the hilum but the renorrhaphy portion of the procedure also can have a significant negative impact on renal function3-5. It is possible to perform this procedure without clamping the hilum and also without formal renorrhaphy. However robust prospective formal evaluation of safety, risks, and potential benefits and whether or not the technique can be employed in a generalized fashion has not been studied.\n\nDemonstration of safety and generalizability may open a whole new avenue of approaching nephron sparing and renal function sparing kidney surgery and decrease potential risks for long term kidney disease in patients with renal masses. This study will investigate the safety, efficacy, and generalizability of the use of clampless, sutureless partial nephrectomy in the treatment of renal cell carcinoma.",[27],[238,239,240,241,242,243],"partial nephrectomy","renal hilar clamping","renal masses","sutureless","clampless","kidney",{"date":245,"type":34},"2026-06-08",{"date":247,"type":34},"2025-06-10",{"date":249,"type":21},"2027-01",{"name":251,"class":67},"University of Florida",{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":262,"studyType":161,"phases":4,"briefSummary":263,"conditions":264,"keywords":276,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":302,"leadSponsor":304,"locationsCount":306},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988","NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.",{"count":261,"type":21},2000,"3 Years","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[265,266,267,268,269,270,110,271,27,272,273,274,275],"Liver Cancer (Primary and Metastatic)","Lung Cancer (Diagnosis)","Bone Cancer Metastatic","Bone Cancer Tumor","Kidney Tumors","Renal Cancer","Renal Cell Carcinoma (Kidney Cancer)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,84,294,295,296,297],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","2026-06-03",{"date":300,"type":34},"2026-06-09",{"date":31,"type":21},{"date":303,"type":21},"2030-12-31",{"name":305,"class":67},"Mark C Burgmans, MD PhD",3,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":323,"leadSponsor":325,"locationsCount":327},"100639579","phase-2-anlotinib--benmelstobart-vs-surgery-for-patients-with-localized-renal-cell-carcinoma-scheduled-to-undergo-partial-nephrectomy-100639579","NCT07627464","Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy","A Multicenter, Randomized Controlled Phase II Study of Neoadjuvant Anlotinib Hydrochloride Capsules Combined With Benmelstobart Injection Versus Surgery Alone for Localized Renal Cell Carcinoma Planned for Partial Nephrectomy","ALTER-UC-011","Inclusion Criteria:\n\n1. Aged between 18 and 75 years, inclusive.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n3. Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy.\n4. Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n5. No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy.\n\nExclusion Criteria:\n\n1. Subjects with a solitary kidney tumor.\n2. Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2).\n3. Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau \\[VHL\\] disease).\n4. Subjects with a prior history of renal transplantation.",{"count":316,"type":21},144,[24],"Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy",[27],"2026-05-31",{"date":214,"type":34},{"date":320,"type":21},{"date":324,"type":21},"2029-12-31",{"name":326,"class":67},"Tianjin Medical University Cancer Institute and Hospital",14,{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":345,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":4},"100639971","phase-3-long-term-extension-study-for-participants-previously-enrolled-in-an-exelixis-sponsored-study-100639971","NCT07620574","Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","Key Inclusion Criteria:\n\n* Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation\u002Fwithdrawal criteria).\n* Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.\n* Able to comply with the long-term extension study protocol as determined by the investigator.\n* Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.\n\nKey Exclusion Criteria:\n\n* Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.\n* Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.\n* Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.\n* Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).\n* Concurrent participation in any therapeutic clinical trial (other than the parent study).\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":335,"type":21},5000,[54],"The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.",[339,27,340,341,110,342,115,343,344],"Cancer","Pancreatic Neuroendocrine Tumors (pNET)","Extra-Pancreatic NET (epNET)","Differentiated Thyroid Cancer (DTC)","Colorectal Cancer","Prostate Cancer",[27,340,341,110,342,115,343],"2026-05-27",{"date":348,"type":34},"2026-06-02",{"date":320,"type":21},{"date":351,"type":21},"2030-05-31",{"name":124,"class":41},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":362,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":382},"100467171","phase-2-phase-2-study-for-the-patient-who-has-diagnosed-with-small-cell-lung-cancer-sclc-or-non-small-cell-lung-cancer-nsclc-or-renal-cell-carcinoma-rcc-and-finished-the-first-line-stand-treatment--need-more-treatment-100467171","NCT05363280","Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment","Major Inclusion Criteria:\n\n1. Male or female, 18 years of age or older\n2. ECOG performance status of 0 or 1\n3. Histologically or cytologically confirmed SCLC \u002FNSCLC\u002FRCC\n4. Have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1\n5. Have a life expectancy of at least 3 months\n\nMajor Exclusion Criteria:\n\n1. Serious, non-healing wound, ulcer or bone fracture\n2. Major surgical procedure within 28 days or minor surgical procedure performed within 7 days prior to treatment\n3. Active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels\n4. Clinically significant cardiovascular disease including uncontrolled hypertension; myocardial infarction or unstable angina within 6 months prior to enrollment; New York Heart Association (NYHA) Grade II or greater congestive heart failure serious cardiac arrhythmia requiring medication; and Grade II or greater peripheral vascular disease\n5. Hemoptysis within 3 months prior to enrollment\n6. Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19 within 14 days prior to enrollment and during the study unless there is an emergent or life-threatening medical condition that required it.\n\nMore information available upon request",{"count":361,"type":21},80,[24],"This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .",[365,27,366],"Small Cell Lung Cancer","Non-Small Cell Lung",[368,369,370,371,372,167],"Recurrent small cell lung caner","Advanced small cell lung cancer","Metastatic Small lung cancer","≥2nd Line treatment","Non small cell lung cancer","2026-05-05",{"date":375,"type":34},"2026-05-08",{"date":377,"type":34},"2022-11-01",{"date":379,"type":21},"2028-12",{"name":381,"class":41},"Advenchen Pharmaceuticals, LLC.",7,{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":391,"enrollmentInfo":392,"targetDuration":394,"studyType":161,"phases":4,"briefSummary":395,"conditions":396,"keywords":402,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":42},"100601955","validation-of-rcc-predicting-model-with-emulated-target-trial-100601955","NCT07117227","Validation of RCC Predicting Model With Emulated-target Trial","Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus","RCCETT","Inclusion Criteria:\n\n* Adults ≥18 years of age;\n* Diagnosis of primary renal cell carcinoma before and during the surgery;\n* Received radical nephrectomy\u002Fnephron-sparing surgery.\n\nExclusion Criteria:\n\n* Subjects with severely missing clinical information;\n* History of other malignant tumors.\n* Recurrence observed before first postoperative follow-up.\n* Discontinue the adjuvant treatment within in the first two course because of severe adverse react.","80 Years",{"count":393,"type":21},4700,"2 Years","This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high\u002Fmedium\u002Flow risk) improves survival outcomes .",[271,27,397,398,399,400,401],"Tumor Thrombus","Prognosis","Prognostic Cancer Model","Real World Study","Observational Study",[403,404,405,406],"renal cell carcinoma","tumor thrombus","prognostic model","emulated-target trial","2026-04-08",{"date":409,"type":34},"2026-04-14",{"date":411,"type":34},"2025-09-01",{"date":413,"type":21},"2027-08-01",{"name":415,"class":67},"Peking University Third Hospital",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":42},"100623859","cbct-guided-markerless-sbrt-for-renal-cell-cancer-100623859","NCT07402109","CBCT Guided Markerless SBRT for Renal Cell Cancer","Organ Sparing Marker-less CBCT-guided Stereotactic Adaptive Radiotherapy for Primary Non-metastasized Renal Tumors","CT-STARRS","Inclusion Criteria:\n\n* Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence\n* No metastatic lesions\n* Patients must be 18 years or older\n* Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.\n\nWritten informed consent\n\nExclusion Criteria:\n\n* Previous high-dose radiotherapy in the region of the kidney",{"count":425,"type":21},40,[189],"This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques",[27],"2026-04-03",{"date":407,"type":34},{"date":432,"type":34},"2026-04-01",{"date":434,"type":21},"2030-01-01",{"name":436,"class":67},"Erasmus Medical Center",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":453,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":223},"100608132","phase-3-phase-3-study-to-assess-safety-and-efficacy-of-177lu-tlx250-in-advanced-relapsed-or-recurrent-ccrcc-100608132","NCT07197580","Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC)","LUTEON","Inclusion Criteria:\n\n* be aged ≥ 18 years.\n* have provided written informed consent, dated and signed by the participant prior to any study-specific procedure;\n* have relapsed or recurrent, locally advanced, or metastatic RCC with histologically or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer Staging Manual (Edge SB et al., 2017), with or without sarcomatoid features;\n* have received at least 2 and no more than 3 prior lines of systemic therapies for locally advanced or metastatic ccRCC including a PD-1\u002FPD-L1 inhibitor (at least 2 administrations) and a VEGF\u002FVEGFR-targeting agent (including TKI or mAb) in sequence or in combination;\n* have had radiographic disease progression occurring during or after the most recent line of therapy or intolerance to most recent line of therapy;\n* have at least one measurable lesion according to RECIST, version 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;\n* be CAIX-positive at Screening defined as having at least 1 lesion with a tumor-lesion CAIX ratio of the maximum standardized uptake value (SUVmax) to liver mean standardized uptake value SUVmean) ≥ 1.5 as determined by BICR of 89Zr-TLX250 PET outcomes;\n* have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1;\n* have recovered from the AEs related to prior lines of therapy or returned to baseline with the exception of Grade 2 neurotoxicity. Ongoing, controlled AEs, such as hypothyroidism or hypertension, are permitted;\n* have adequate organ function, defined as:\n* Bone Marrow:\n\n  * leukocytes ≥ 3,000\u002FµL;\n  * absolute neutrophil count ≥ 1500\u002FµL (administration of granulocyte colony stimulating factor is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250;\n  * platelets ≥ 100,000\u002FµL (platelet transfusion is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250); and\n  * hemoglobin ≥ 9g\u002FdL (red blood cell transfusion is not allowed within 2 weeks prior to the first administration of 177Lu-TLX250).\n* Liver Function:\n\n  * total bilirubin ≤ 1.5 × the upper limit of normal (ULN). For patients with known Gilbert's Syndrome ≤ 3 × ULN is permitted; and\n  * alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5.0 × ULN for participants with liver metastases.\n* Renal Function:\n\n  * creatinine clearance ≥ 40 mL\u002Fmin as measured by Cockroft-Gault formula or directly calculated by 24h urine;\n  * have negative pregnancy test for women of childbearing potential (serum); and\n\nExclusion Criteria:\n\n* have any of the following:\n\n  * visceral metastatic lesions that are ≥ 1 cm that have a CAIX TLR \\\u003C 1;\n  * lytic bone metastatic lesions with a soft tissue component of at least 1 cm with a TLR \\\u003C 1; and\u002For\n  * at least one metastatic lymph node lesion with short axis ≥ 2.5 cm with a TLR \\\u003C1;\n* received prior 177Lu-TLX250 therapy, any other radioligand therapy, or any prior CAIX-targeting therapy;\n* have any known hypersensitivity to compounds of similar chemical or biologic composition to girentuximab, DFO or DOTA linker, zirconium or lutetium, and\u002For any excipient in the study drug or radiographic contrast-agents;\n* has received G-CSF or erythropoietin within 4 weeks prior to laboratory evaluations at Screening;\n* be currently receiving or have received:\n\n  * any radionuclide within 10 half-lives of the radionuclide prior to 89Zr-TLX250 administration;\n  * any type of systemic anticancer therapy within 2 weeks before the first administration of 177Lu-TLX250;\n  * prior radiotherapy within 2 weeks prior to the first administration of 177Lu-TLX250 (must have recovered from all radiation-related toxicities and not currently require steroid treatment); and\u002For\n  * prior palliative radiation (≤2 weeks of radiotherapy) within 1-week of the first administration of 177Lu-TLX250 for non-central nervous system disease; NOTE: If the investigator feels that the patient is continuing to receive some clinical benefit from standard-of-care (SOC) therapy, the patient may continue SOC therapy up until 2 weeks prior to dosing with 177Lu-TLX250.\n* have known brain metastases, unless these have been treated and stabilized for at least 4 weeks prior to the first administration of 177Lu-TLX250; Note: Participants with a history of brain metastases must have either a head CT with contrast-or brain MRI performed at Screening to document stable disease prior to the first administration of 177LuTLX250.\n* Have experienced any major trauma including major surgery (such as abdominal\u002F cardiac\u002Fthoracic surgery) within 3 weeks of administration of the first administration of 177LuTLX250;\n* be pregnant or intend to become pregnant, breastfeed, or conceive a child during the study period and for at least 42 days after last administration of 89Zr-TLX250 or 6 months after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;\n* Note: Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see Appendix 10.4).\n* be planning to breastfeed during the study period and for 28 days after last administration of 89ZrTLX250 or 75 days after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;\n* have active and uncontrolled infections requiring systemic therapy or other severe concurrent disease, which, in the opinion of the investigator, would place the participant at undue risk or interfere with the study;\n* have a history of concurrent malignancy with a life expectancy of ≤ 2 years or requirement of systemic anti-cancer therapy or requirement of local therapy that would confound study results; however; participants with the following malignancies can be enrolled into the study:\n\n  * basal cell or squamous cell carcinoma of the skin;\n  * carcinoma in situ of the cervix, breast or bladder; and\u002For\n  * incidental histologic finding of prostate cancer;\n* have a serious, non-healing wound, ulcer, or bone fracture;\n* be unable to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan;\n* have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, and\u002For stable Grade 2 sensory neuropathy, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0;\n* have inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, etc.);\n* have a life expectancy shorter than 3 months;\n* have bleeding or thrombotic disorders or subjects at risk for severe hemorrhage;\n* have experienced any clinically significant bleeding, including hemoptysis or tumor bleeding within 2 weeks prior to the first administration of 177Lu-TLX250;\n* has evidence of a serious active or sub-clinical infection or angina pectoris (New York Heart Association \\[NYHA\\] Class III or IV), significantly prolonged QT interval or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, that might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment; or\n* have any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in a clinical study.",{"count":425,"type":21},[54],"Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.",[449,271,27,450,451,452],"ccRCC","Renal Cell Cancer Metastatic","Renal Cell Cancer, Recurrent","Clear Cell Renal Cell Cancer (ccRCC)",[454,455,456,449,457,458,459,460,461,462,463,464,465],"Carbonic anhydrase 9","Clear Cell Renal Cell Cancer","Kidney Cancer","CA9","CA-9","CAIX","Girentuximab","CA9 target therapy","Positron-Emission Tomography","Radiation Therapy","Radiopharmaceuticals","Targeted Radiation","2026-03-26",{"date":432,"type":34},{"date":469,"type":34},"2026-03-25",{"date":471,"type":21},"2029-02-28",{"name":473,"class":41},"Telix Pharmaceuticals (Innovations) Pty Limited",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":391,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":42},"100631229","ischemic-preconditioning-reduces-the-severity-of-acute-kidney-injury-after-partial-nephrectomy-100631229","NCT07497958","Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy","Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy: a Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Patients who are scheduled to undergo partial nephrectomy, with no specific surgical procedure limitation, including laparoscopic surgery, robot-assisted surgery, and open surgery\n* Aged 18 to 80\n* Possess good organ function status: sufficient organ function (based on the normal values of the clinical trial center)\n\n  1. Blood routine test: WBC≥3.5×10\\^9\u002FL, absolute neutrophil count ≥1.5×10\\^9\u002FL, PLT≥75.0×10\\^9\u002FL, HGB≥80g\u002FL;\n  2. Liver function: Total bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;\n\nExclusion Criteria:\n\n* The anesthesiologist assesses that the patient cannot tolerate general anesthesia surgery\n* Individuals with severe cardiovascular and cerebrovascular diseases, uncontrolled hypertension, and diabetes\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m²\n* Horseshoe kidney\n* Solitary kidney\n* Pregnant women",{"count":482,"type":21},174,[189],"It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy.",[27,486],"Renal Function Abnormal",[486,488,489,490],"Acute kidney injury","Partial nephrectomy","Ischemic preconditioning","2026-03-23",{"date":493,"type":34},"2026-03-27",{"date":432,"type":21},{"date":496,"type":21},"2028-12-31",{"name":498,"class":67},"Sun Yat-sen University",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":185,"sex":17,"minAge":505,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":42},"100628396","laparoscopic-versus-open-nephrectomy--clinical-effectivness-and-cost-analysis-100628396","NCT07461090","Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis","Inclusion Criteria:\n\n* American Society of Anesthesiology score 1-3.\n* Indication for :\n\n  * Simple total nephrectomy or hemi nephrectomy: benign chronic inflammatory non-functioning kidney\n  * Partial nephrectomy: localized renal mass ≤7 cm suitable for nephron-sparing surgery.\n  * Radical nephrectomy or Radical nephrouretrectomy with bladder cuff: localized renal tumor requiring complete nephrectomy without major vascular invasion.\n* Patient deemed fit for general anesthesia and surgery.\n* Patient provides written informed consent.\n\nExclusion Criteria:\n\n* emergency surgery, dialysis-dependent patients, planned hybrid procedures.\n* Patients with incomplete data\n* Patients with metastatic disease at presentation.\n* Prior extensive ipsilateral retroperitoneal surgery or severe adhesions precluding Laparoscopy.\n* Need for concomitant major procedures (eg, large bowel resection) at index operation.\n* Locally advanced tumor with obvious major vascular involvement requiring complex vascular reconstruction.\n* Uncorrected coagulopathy.\n* Pregnancy or Obese patient (BMI \\> 40)\n* Inability to provide informed consent or comply with follow-up.","1 Year",{"count":507,"type":21},60,[189],"To evaluate and compare clinical effectiveness (operative time, blood loss, hospital stay, complications and etc) and cost analysis' between laparoscopic nephrectomy and open nephrectomy .",[511,27],"Nonfunctioning Kidney",[513,514],"Clinical effectiveness of laparoscopic nephrectomy","Cost analysis of laparoscopic nephrectomy","2026-03-09",{"date":517,"type":34},"2026-03-11",{"date":519,"type":21},"2026-02",{"date":521,"type":21},"2027-02",{"name":523,"class":67},"Menoufia University",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":533,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":42},"100598874","phase-2-cabozantinib-dose-skipping-as-an-alternative-to-dose-reductions-100598874","NCT07077161","Cabozantinib Dose Skipping as an Alternative to Dose Reductions","SKIPPY 2","Inclusion Criteria:\n\n* Willing and able to provide informed consent;\n* Aged 18 years or older;\n* Histologically confirmed advanced renal cell carcinoma;\n* At least 4 weeks on a stable dosage of cabozantinib of 40 mg or 20 mg once daily as single-agent treatment or in combination with nivolumab;\n* Acceptable tolerability and the need for dose reductions or treatment interruptions has been estimated as low;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n* Estimated life expectancy of ≥6 months;\n* No response evaluation planned during the study period.\n\nExclusion Criteria:\n\n* Inability to follow the recommended standard breakfast;\n* Gastrointestinal abnormalities influencing the absorption of cabozantinib, including active inflammatory bowel disease, malabsorption syndrome, and prior major surgery of the stomach, pancreas, liver or small bowel.\n* Use of moderate or strong inhibitor of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including ketoconazole, grapefruit juice, clarithromycin, erythromycin, itraconazole and ritonavir.\n* Use of moderate or strong inducer of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including rifampicin, phenytoin, carbamazepine, phenobarbital and herbal preparations containing St. John's Wort.\n* Use of inhibitor of multidrug resistance-associated protein 2 within 1 month of start of treatment with cabozantinib, including cyclosporine, delavirdine, efavirenz, emtricitabine, benzbromarone and probenecid.",{"count":532,"type":21},34,[24],"The goal of this study is to determine if an alternative cabozantinib dosing regimens results in a similar drug exposure compared to the standard regimens in patients with metastatic renal cell carcinoma (mRCC). All dosages of cabozantinib (20 ,40, 60mg) have the same price, and cabozantinib is eliminated very slowly by the body. This means that using fewer tablets could potentially lead to cost savings, while remaining equally effective.\n\nThe main questions it aims to answer are:\n\n* Is the drug exposure from our experimental regimens similar to the standard dosing regimens?\n* Do the experimental regimens affect the number of side effect and the patients' quality of life?\n\nParticipants will:\n\n* Take cabozantinib according to either the experimental or standard dosage regimen for 4 weeks\n* After 4 weeks: visit the clinic to collect some blood samples and complete two questionnaires.\n* 1 and 3 days after this visit: visit the clinic to collect 1 blood sample.\n* The day after the hospital visit: switch to the other dosing regimen and according to that regimen for another 4 weeks.\n* After 4 weeks: visit the clinic to collect some blood samples and complete two questionnaires\n* 1 and 3 days after this visit: visit the clinic to collect 1 blood sample.",[27],[167,537,538,539],"RCC","Cabozantinib","pharmacokinetics","2026-01-26",{"date":542,"type":34},"2026-01-28",{"date":544,"type":21},"2026-01-01",{"date":546,"type":21},"2028-09-01",{"name":548,"class":67},"dr. Tom van der Hulle",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":22,"phases":558,"briefSummary":559,"conditions":560,"keywords":564,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":42},"100621352","phase-1-sapu003-in-advanced-mtor-sensitive-solid-tumors-100621352","NCT07369505","Sapu003 in Advanced mTOR-sensitive Solid Tumors","A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)","Inclusion Criteria:\n\n1. Sex and Age: Patients must be ≥ 18 years of age at the time of informed consent.\n\n   * Cohort A (HR+\u002FHER2- breast cancer): Eligible patients must be postmenopausal women, defined as women ≥ 18 years of age with amenorrhea for ≥ 12 consecutive months without another pathophysiological cause.\n   * Cohort B (RCC, NETs, TSC-associated tumors, HCC): Eligible patients include both male and female adults with advanced disease.\n2. Cohort A HR+\u002FHER2- Breast Cancer:\n\n   Eligible patients must meet all of the following:\n   * Has histologically or cytologically documented advanced (metastatic or unresectable) hormone receptor-positive, HER2 negative breast cancer (advanced HR+ BC)\n   * Has stage IV or locally advanced breast cancer per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Seventh Edition;\n   * Has failed any combination endocrine therapy or relapse within 6 months of adjuvant chemotherapy for metastatic or locally advanced disease. Prior therapy should have included a non-steroidal aromatase inhibitor unless clinically contraindicated;\n   * Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities.\n3. Cohort B Other Advanced mTOR-Sensitive Solid Tumors:\n\n   Eligible patients must meet all of the following:\n   * Has histologically or cytologically confirmed advanced (metastatic or unresectable) disease in one of the following tumor types:\n\n     * Renal Cell Carcinoma (RCC)\n     * Neuroendocrine Tumors (NETs)\n     * Tuberous Sclerosis Complex (TSC)-associated tumors\n     * Hepatocellular Carcinoma (HCC)\n   * Has disease that is measurable and\u002For evaluable per RECIST v1.1 (or relevant criteria, if applicable).\n   * Has progressed on or is intolerant to at least one prior line of standard therapy appropriate for the specific tumor type, unless no effective standard therapy exists.\n   * Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities.\n4. Patients must be on stable doses of metformin or statin\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n6. Life expectancy ≥ 3 months\n7. Hematology\u002Fchemistry: Patient has adequate hematological, renal, and hepatic function as defined by the following Screening laboratory values obtained within 7 days prior to randomization and assessed based on local labs (patients should not have received a transfusion within 7 days before the Screening laboratory assessments):\n\n   * Absolute neutrophil count (ANC) ≥ 2,000 cells\u002Fmm3 (2 x109\u002FL)\n   * Platelet count ≥ 100,000 cells\u002Fmm3 (100x109\u002FL)\n   * Hemoglobin≥ 9 g\u002FdL\n   * Serum creatinine≤ 1.5 x the upper limit of normal (ULN)\n   * Total bilirubin ≤1.5 x ULN or direct bilirubin ≤1 x ULN for patients with total bilirubin levels \\> 1.5 ULN\n   * AST (SGOT) \u002F ALT (SGPT) ≤ 2.5 x ULN (≤5 x ULN for patients with metastases.)\n   * GFR ≥ 50 mL\u002Fmin\u002F1.73m2 by the CKD-EPI or MDRD formulas.\n8. All other clinical laboratory values deemed as normal or not clinically significant by the Principal Investigator\u002FSub-Investigator.\n9. Breastfeeding: Patients must be non-lactating. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued prior to the first dose of study drug.\n10. Female patients of reproductive potential to avoid becoming pregnant and to use effective contraception during the study and for 8 weeks after the last dose. Male patients with female partners of reproductive potential to use effective contraception during the study and for 4 weeks after the last dose.\n11. Able and willing to adhere to all protocol requirements and study procedures throughout the course of the study.\n12. Ability to comprehend and be informed of the nature of the study, as assessed by study clinic staff\n\nExclusion Criteria:\n\n1. Patients with a history of other malignancies, except for adequately treated non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix, curatively treated in-situ carcinoma of the breast, or other solid tumors curatively treated with no evidence of disease for \\> 5 years.\n2. Patients who have not completely recovered from any toxicities from previous chemotherapy, hormone therapy, immunotherapy, target therapy, or radiotherapies ≥ Grade 1 per NCI CTCAE version 5.0, with the exception of alopecia.\n3. Patients who have received any of the following treatments within the specified timeframes prior to screening:\n\n   * Prior chemotherapy within 30 days prior to screening (42 days for mitomycin C or nitrosoureas).\n   * Prior immunotherapy, prior anti-tumor hormonal therapy (for breast cancer patients), and prior radiotherapy within 30 days prior to screening.\n   * Radiotherapy is not allowed during study. Administration of other chemotherapy, immunotherapy, or anti-tumor hormonal therapy during the study is not allowed.\n4. Patients had major surgery within 30 days prior to randomization, or patients have not recovered from prior major surgery.\n5. Sensory \u002F Peripheral neuropathy of \\> Grade 1 per NCI CTCAE version 5.0 at Screening.\n6. Patients with active brain metastases. Patients with treated brain metastases are eligible provided they have no evidence of active brain disease and are off of definitive therapy (including steroids) at least 3 months prior to randomization.\n7. Known history or presence of any clinically significant disease or condition other than cancer unless determined as not clinically significant by the Principal Investigator\u002FSub-Investigator. This includes, but is not limited to, the following: hepatic, renal\u002Fgenitourinary, gastrointestinal (e.g., intra-abdominal inflammation), cardiovascular (e.g., congestive heart failure, ventricular arrhythmia, myocardial infarction, unstable angina pectoris), cerebrovascular, pulmonary (e.g., interstitial lung disease), endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological, or hematological (e.g., bleeding diathesis or coagulopathy).\n8. History of difficulty with donating blood or difficulty in accessibility of central line.\n9. Known history or presence of:\n\n   * Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C (serology to confirm absence is required within 7 days prior to randomization and assessed based on local labs);\n   * Alcohol abuse or dependence within one year prior to randomization;\n   * Drug abuse or dependence (marijuana, amphetamines, barbiturates, cocaine, opiates and benzodiazepines);\n   * Hypersensitivity or idiosyncratic reaction to everolimus, other rapamycin derivatives or its excipients\n   * Severe allergic reactions (e.g., anaphylactic reactions, angioedema).\n10. Patients may not participate in any other clinical protocol or investigational trial that involves administration of experimental therapy and\u002For the use of investigational devices with therapeutic intent within 30 days prior to randomization and while enrolled in this study. Caution is recommended when administering Sapu003 and concomitantly with known substrates, PgP inhibitors, inhibitors, and inducers of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.\n11. Use of any strong inhibitors of cytochrome P450 (CYP) enzymes (e.g., fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (e.g., barbiturates (phenobarbital), carbamazepine, phenytoin and rifampin), in the previous 14 days before randomization until the last blood draw in the study.\n12. Acute active infection requiring antibiotics, antiviral agents, or antifungal agents within 14 days prior to randomization\n13. Pregnant or lactating women.",{"count":557,"type":21},27,[80],"This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+\u002FHER2-negative breast cancer, renal cell carcinoma \\[RCC\\], neuroendocrine tumors \\[NETs\\], tuberous sclerosis complex \\[TSC\\]-associated tumors, and hepatocellular carcinoma \\[HCC\\]).",[561,27,562,563,110],"Breast Cancer Metastatic","Neuroendocrine Tumors","Tuberous Sclerosis Complex (TSC)",[565,566,567,27,568,563,110,569,570],"Sapu003","Everolimus for Injection","mTOR-Sensitive Solid Tumors","Neuroendocrine Tumors (NETs)","everolimus","HR+\u002FHER2-negative breast cancer","2026-01-17",{"date":573,"type":34},"2026-01-27",{"date":575,"type":34},"2025-12-15",{"date":577,"type":21},"2026-12",{"name":579,"class":41},"SAPU NANO (US) LLC",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":589,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":42},"100606912","phase-1-cd70-targeted-car-t-therapy-in-cd70-positive-advanced-solid-tumors-100606912","NCT07181720","CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors","Clinical Study of CD70-Targeted Chimeric Antigen Receptor T Lymphocytes (CAR-T) in Advanced CD70-Positive Malignant Solid Tumors","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender;\n2. Histologically or cytologically confirmed advanced\u002Fmetastatic solid tumors (tumors with positive CD70 expression, confirmed histopathological ly with IHC 3+ score);\n3. Failed or intolerant to standard second-line treatments (at least one of the following: tyrosine kinase inhibitors (TKIs), poly(ADP-ribose) polymerase inhibitors (PARPi), anti-angiogenic therapy; disease progression or inability to tolerate surgery, chemotherapy, radiotherapy, or targeted therapy);\n4. At least one measurable lesion per RECIST 1.1 criteria, with measurable lesions defined as:\n\n   1. Extranodal lesions with a long axis ≥10mm on CT scan;\n   2. Lymph node lesions with a short axis ≥15mm on CT scan;\n   3. CT slice thickness ≤5mm.\n5. ECOG performance status of 0-2 ;\n6. Expected survival ≥12 weeks;\n7. No history of severe psychiatric disorders;\n8. Adequate organ function as defined by the following:\n\n   1. Hematology: White blood cell count \\>2.0×10⁹\u002FL, neutrophils \\>0.8×10⁹\u002FL, lymphocytes \\>0.5×10⁹\u002FL, platelets \\>50×10⁹\u002FL, hemoglobin \\>90g\u002FL;\n   2. Cardiac: Echocardiogram showing left ventricular ejection fraction (LVEF) ≥50%, and ECG with no significant abnormalities;\n   3. Renal: Serum creatinine ≤2.0×ULN;\n   4. Hepatic: ALT and AST ≤3.0×ULN (may be relaxed to ≤5.0×ULN in cases with liver tumor infiltration); total bilirubin ≤2.0×ULN (may be relaxed to ≤3.0×ULN in cases with Gilbert's syndrome or liver tumor infiltration);\n   5. Oxygen saturation ≥92% without supplemental oxygen;\n9. Ability to undergo single or venous blood collection, with no contraindications to cellular collection;\n10. Female subjects must agree to use reliable contraception (excluding fertility awareness methods) from the time of informed consent until 1 year after CAR-T cell infusion;\n11. Subject or authorized guardian agrees to participate in the trial and signs the informed consent form (ICF), indicating understanding of the trial's purpose and procedures and willingness to participate.\n\nExclusion Criteria:\n\n1. Prior treatment with anti-CD70 therapies;\n2. Active\u002Fsymptomatic central nervous system (CNS) metastasis or meningeal metastasis: Subjects with treated brain metastases are eligible if treatment was completed ≥4 weeks prior to screening and there is no evidence of progression on imaging;\n3. Prior treatments within specified time frames:\n\n   1. Participation in other interventional clinical trials within 3 months before cell infusion (for unapproved drugs, the last dose must be ≥3 months prior; for approved drugs, ≥5 half-lives prior to cell infusion);\n   2. Received chemotherapy or targeted therapy within 2 weeks prior to blood collection or within 5 half-lives of the drug (whichever is shorter);\n   3. Received \\>10mg\u002Fday prednisone (or equivalent) within 2 weeks prior to blood collection, unless for adrenal replacement or inhaled\u002Flocal steroids (except for active autoimmune disease);\n   4. Received live attenuated vaccines within 4 weeks prior to screening;\n4. Active infection requiring systemic treatment or uncontrolled infection within 1 week before screening;\n5. History of any other malignancy within the past 3 years, except for treated and stable non-melanoma skin cancer or malignancies treated with curative intent and no evidence of active disease for ≥3 years;\n6. Cardiovascular conditions:\n\n   1. NYHA Class III or IV heart failure;\n   2. Myocardial infarction or coronary artery bypass graft (CABG) within 6 months prior to screening;\n   3. Clinically significant ventricular arrhythmias or unexplained syncope (excluding vasovagal or dehydration);\n   4. Severe non-ischemic cardiomyopathy;\n7. Active or uncontrolled autoimmune diseases such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, etc.;\n8. Positive for HBsAg or HBcAb with elevated HBV DNA in peripheral blood; positive for HCV antibodies with detectable HCV RNA levels; positive for HIV antibodies; positive syphilis test;\n9. Toxicity from prior anti-tumor treatments has not resolved to baseline or ≤grade 1, except for alopecia or peripheral neuropathy;\n10. History of venous thromboembolism (e.g., pulmonary embolism) requiring ongoing anticoagulation treatment, or meeting one of the following criteria:\n\n    1. Severe bleeding (grade 3 or 4) lasting for ≥30 days;\n    2. Post-thrombotic sequelae (e.g., persistent dyspnea and hypoxia) due to venous thromboembolism;\n11. Pregnant or breastfeeding women;\n12. Other conditions that, in the opinion of the investigator, make the subject unsuitable for participation in the trial.",{"count":588,"type":21},90,[80],"This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced malignancies were obtained and the recommended dose and infusion schedule.",[27,592,593,594,595,596],"Lung Cancer","Anaplastic Thyroid Carcinomas","Ovarian Cancer","Cervical Cancer","Thymic Carcinoma","2025-09-28",{"date":599,"type":34},"2025-10-02",{"date":601,"type":34},"2025-09-12",{"date":603,"type":21},"2028-05-31",{"name":605,"class":41},"Chongqing Precision Biotech Co., Ltd",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":617,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":42},"100606194","phase-2-preoperative-therapy-of-super-selective-tumor-artery-embolization-combined-with-toripalimab-and-axitinib-in-advanced-rcc-100606194","NCT07172386","Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC","A Study on the Safety and Efficacy of Super-selective Tumour Arterial Embolisation in Combination With Toripalimab and Axitinib as a Preoperative Treatment for Advanced Renal Cell Carcinoma","Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Age ≥ 18 years\n* Patients with pathologically and radiographically confirmed renal cell carcinoma:\n\n  * cT2N0M0 with Grade 4 or sarcomatoid feature;\n  * cT3-4N0M0;\n  * cTanyN1M0;\n  * M1 that can be returned to M0 through local therapy\n* Preoperative imaging evaluation can be performed radical excision or tumor reduction surgery\n* There are no suspected brain metastases\n* The presence of measurable lesions was assessed according to RECISTv1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Organ function level must meet the following requirements: Hematological indexes: neutrophil count \\>= 1.5x10\\^9\u002FL, platelet count \\>= 100x10\\^9\u002FL, hemoglobin \\>= 9.0 g\u002Fdl (can be maintained by blood transfusion); Liver function: total bilirubin \\\u003C=1.5 ULN, alanine aminotransferase and aspartate aminotransferase \\\u003C=1.5 ULN\n* Non-surgically sterilized or reproductive-age female patients must use a medically approved contraceptive method (such as an intrauterine device, oral contraceptives, or condoms) during the study treatment period and for 3 months after its completion; Female patients who are not surgically sterilized or are of childbearing potential must have a negative serum or urine HCG test within 7 days prior to study enrollment and must not be lactating. Male patients who are not surgically sterilized or are of childbearing potential must agree to use one medically approved contraceptive method with their spouse during the study treatment period and for 3 months after the study treatment period ends.\n* The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up\n\nExclusion Criteria:\n\n* Prior receipt of radiotherapy, chemotherapy, long-term or high-dose corticosteroid therapy, surgery, or molecular targeted therapy\n* Subjects with a history of or concurrent other malignancies (except those controllable and not affecting 2-year survival)\n* Prior treatment with other PD-1\u002FPD-L1 therapies; Known history of allergy to macromolecular protein preparations or any known PD-1 component\n* Active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; Subjects with vitiligo or childhood asthma that has achieved complete remission without requiring any intervention in adulthood may be included; subjects requiring medical intervention with bronchodilators for asthma are excluded);\n* Subjects currently using immunosuppressive agents for immunosuppression purposes and continuing such use within 2 weeks prior to enrollment\n* Uncontrolled cardiac clinical symptoms or diseases, such as:\n\n  * New York Heart Association (NYHA) Class II or higher heart failure;\n  * Unstable angina;\n  * Myocardial infarction within the past year;\n  * Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention\n* Coagulation abnormalities (PT \\> 16s, APTT \\> 43s, TT \\> 21s, Fbg \\> 2g\u002FL) with bleeding tendency or currently receiving thrombolytic or anticoagulant therapy;\n* Active gastrointestinal bleeding within 3 months prior to first dose due to esophageal varices, active gastric or duodenal ulcer, ulcerative colitis, portal hypertension, or unresected tumors; or other conditions judged by the investigator to potentially cause gastrointestinal bleeding or perforation\n* History or current presence of major bleeding (≥30 mL within 3 months), hemoptysis (≥5 mL fresh blood within 4 weeks), or thromboembolic events (including stroke and\u002For transient ischemic attack) within 12 months\n* Active infection or unexplained fever \\>38.5°C occurring during screening or prior to first dose\n* History of abdominal fistula, gastrointestinal perforation, or abdominal abscess within 4 weeks prior to first dose\n* Objective evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or severe pulmonary impairment\n* Subjects with congenital or acquired immunodeficiency, such as HIV infection, or active hepatitis (transaminase levels not meeting inclusion criteria; for hepatitis B: HBV DNA ≥10⁴\u002Fml; for hepatitis C: HCV RNA ≥10³\u002Fml); chronic hepatitis B virus carriers with HBV DNA ≥2000 IU\u002Fml (≥10⁴ copies\u002Fml) must concurrently receive antiviral therapy during the study to be eligible for enrollment\n* Subjects currently participating in other clinical studies or those who completed a prior clinical study within the past month; subjects may receive other systemic antitumor therapies during the study period\n* Administration of live vaccines within 4 weeks prior to study drug initiation or during the study period\n* Known history of psychiatric drug abuse, alcoholism, or substance abuse;\n* Inability or refusal to bear out-of-pocket costs for examinations and treatments\n* The investigator deems the subject should be excluded from this study, such as when the investigator determines the subject has other factors that may necessitate premature termination of the study, including: other serious illnesses (including psychiatric disorders) requiring concomitant treatment, severe laboratory abnormalities, or family\u002Fsocial factors that may compromise subject safety or interfere with data\u002Fsample collection.",{"count":425,"type":21},[24],"This is a phase II study to determine the efficacy and safety of Super-selective tumor artery embolization combined with toripalimab and axitinib as treatment for patients with the advanced kidney cancer . Further evaluate whether the treatment plan is beneficial to the patient's operation. Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for three to four consecutive cycles combined with axitinib administered for four consecutive cycles in the preoperative and patients need to continue taking the drug for a year after surgery",[27],[166,618,619,620],"Axitinib","Super-selective renal artery embolization","Advanced Renal Cell Carcinoma","2025-09-13",{"date":623,"type":34},"2025-09-16",{"date":625,"type":34},"2025-07-31",{"date":627,"type":21},"2027-07-31",{"name":176,"class":67},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":22,"phases":638,"briefSummary":639,"conditions":640,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":42},"100606432","phase-2-petct-directed-free-of-therapy-for-metastatic-rcc-patients-with-imdc-favorable-or-intermediate-risk-100606432","NCT07175480","PET\u002FCT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk","An Open-label, Investigator-initiated, Single Arm, Exploratory Phase 2 Trial Evaluating the Feasibility and Efficiency of PET\u002FCT Directed Free of Therapy Used for Metastatic and Advanced Renal Cell Carcinoma","Perfumer","Pre-screening Inclusion Criteria:\n\n1. Male or female subjects aged ≥ 18 years at time of signing informed consent\n2. Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC (American Joint Committee on Cancer \\[AJCC\\] Stage IV)\n3. Favorable or intermediate risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. Eastern Cooperative Oncology Group performance status 0 or 1\n5. Karnofsky Performance Status (KPS) grade ≥ 70%\n6. Adequate organ and bone marrow function meeting all laboratory criteria:\n\n   Ⅰ. Absolute neutrophil count (ANC) ≥ 1.5 × 10³\u002FμL (≥ 1.5 GI\u002FL); Platelet count ≥ 100 × 10³\u002FμL (≥ 100 GI\u002FL); Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL)\n\n   Ⅱ. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 × upper limit of normal. Total bilirubin ≤ 1.5 × the upper limit of normal (≤ 3 mg\u002FdL \\[≤ 51.3 μmol\u002FL\\] if Gilbert's syndrome)\n\n   Ⅲ. Serum creatinine ≤ 2.0 × upper limit of normal or calculated creatinine clearance ≥ 30 mL\u002Fmin using the Cockroft-Gault formula.\n7. Capacity to comprehend and comply with protocol requirements, with documented informed consent signed\n8. Contraception agreement for sexually active fertile participants and partners to use of medically accepted methods during study and continue for 5 months after last treatment\n9. Negative pregnancy status at screening for women of childbearing potential\n\nPre-screening Exclusion Criteria:\n\n1. Highly malignant pathology\n2. Prior systemic therapy for advanced RCC\n3. Poor risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. ECOG performance status \\>1\n5. Karnofsky Performance Status (KPS) \\\u003C70%\n6. Inadequate organ and bone marrow function\n7. Bulky or symptomatic disease or hepatic metastases\n8. Active brain metastases or leptomeningeal disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 3 months before the start of treatment.\n9. Concurrent or prior invasive malignancies that could confound efficacy assessment, except adequately treated non-melanoma skin cancer, superficial bladder cancer or carcinoma in situ of the cervix\u002Fbreast with curative therapy \\>3 years ago.\n10. Uncontrolled hypertension (\\>150\u002F100 mmHg despite optimal therapy)\n11. Uncontrolled comorbidities within 6 months including but not limited to: clinically significant cardiovascular disorders, gastrointestinal disorders with high risk of perforation or fistula formation, significant hematuria, hematemesis, hemoptysis, or major bleeding history, severe infections, severe autoimmune diseases (e.g., systemic lupus erythematosus, immune pneumonitis), active HIV, HBV, or HCV infections.\n12. Major surgery within 4 weeks with unhealed wounds or planned surgery during study\n13. Concomitant use of drugs or substances affecting activity or pharmacokinetics of investigational products\n14. Hypersensitivity to any component of study drugs\n15. Chronic or concurrent immunosuppressive therapy, except Inhaled\u002Ftopical steroids\n16. Medical\u002Fpsychiatric\u002Fsocial conditions compromising protocol compliance\n17. Pregnancy, lactation, or refusal of contraception during and for 5 months post-treatment\n18. Inability to undergo PET\u002FCT or oral drug administration\n\nMain-screening Inclusion Criteria:\n\n1. Patient must receive≥12 months of first line treatment with the combination of PD-1\u002FPD-L1 ICI and VEGFR-TKI, and have not experienced a toxicity that prevents them from continuing on therapy.\n2. Patients must achieve complete metabolic response (CMR) or partial metabolic response (PMR) on PET\u002FCT within 24 months of the combination treatment with PD-1\u002FPD-L1 ICI and VEGFR-TKI.\n3. Favorable or intermediate risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. Eastern Cooperative Oncology Group performance status 0 or 1\n5. Karnofsky Performance Status (KPS) grade ≥ 70%\n6. Adequate organ and bone marrow function meeting all laboratory criteria:\n\n   Ⅰ. Absolute neutrophil count (ANC) ≥ 1.5 × 10³\u002FμL (≥ 1.5 GI\u002FL); Platelet count ≥ 100 × 10³\u002FμL (≥ 100 GI\u002FL); Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL)\n\n   Ⅱ. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 × upper limit of normal. Total bilirubin ≤ 1.5 × the upper limit of normal (≤ 3 mg\u002FdL \\[≤ 51.3 μmol\u002FL\\] if Gilbert's syndrome)\n\n   Ⅲ. Serum creatinine ≤ 2.0 × upper limit of normal or calculated creatinine clearance ≥ 30 mL\u002Fmin using the Cockroft-Gault formula.\n7. Capacity to comprehend and comply with protocol requirements, with documented informed consent signed\n8. Contraception agreement for sexually active fertile participants and partners to use of medically accepted methods during study and continue for 5 months after last treatment\n9. Negative pregnancy status at screening for women of childbearing potential\n\nMain-screening Exclusion Criteria:\n\n1. Failure to complete ≥12 months of first-line PD-1\u002FPD-L1 + VEGFR-TKI therapy due to unmanageable toxicity or other reasons\n2. Failure to achieve CMR or PMR on PET\u002FCT within 24 months after combination therapy; new metastatic lesions or disease progression on PET\u002FCT.\n3. Poor risk as per International Metastatic RCC Database Consortium (IMDC) criteria\n4. ECOG performance status \\>1\n5. Karnofsky Performance Status (KPS) \\\u003C70%\n6. Inadequate organ and bone marrow function\n7. Uncontrolled hypertension (\\>150\u002F100 mmHg despite optimal therapy)\n8. Uncontrolled comorbidities including but not limited to: clinically significant cardiovascular disorders, gastrointestinal disorders with high risk of perforation or fistula formation, significant hematuria, hematemesis, hemoptysis, or major bleeding history, severe infections, severe autoimmune diseases (e.g., systemic lupus erythematosus, immune pneumonitis), active HIV, HBV, or HCV infections.\n9. Medical\u002Fpsychiatric\u002Fsocial conditions compromising protocol compliance\n10. Pregnancy, lactation, or refusal of contraception during study period.\n11. Inability to undergo PET\u002FCT or oral drug administration\n\nWithdrawal Criteria:\n\n1. Disease progression with unsatisfactory efficacy, or occurrence of intercurrent illnesses during treatment or follow-up period.\n2. Occurrence of severe treatment-related adverse reactions.\n3. Laboratory test results indicating critical safety values.\n4. Voluntary withdrawal of informed consent by the patient.\n5. Investigator's judgment that withdrawal is in the subject's best interest.\n6. Pregnancy during the trial period.\n7. Wrong Enrollees: deviation of inclusion or exclusion criteria.\n8. Poor patient compliance.\n9. Loss to follow-up or death during the trial period.",{"count":20,"type":21},[24],"This phase 2 trial aims to test the feasibility and efficiency of PET\u002FCT-directed treatment interruption strategy in metastatic renal cell carcinoma patients with IMDC favorable\u002Fintermediate risk who achieve complete (CMR) or partial metabolic response (PMR) after ≥12 months of first-line PD-1\u002FPD-L1 Immune checkpoint inhibitor (ICI)+ VEGFR-tyrosine kinase inhibitor (TKI) therapy. It helps figure out whether PET\u002FCT can safely direct treatment pause as well as explores a new individualized treatment option based on metabolic imaging for RCC patients.",[27,641],"Metastatic Renal Cell Carcinoma (mRCC)",{"date":623,"type":34},{"date":644,"type":34},"2025-01-24",{"date":646,"type":21},"2030-08",{"name":648,"class":67},"Jinling Hospital, China",{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":4,"eligibilityCriteria":655,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":22,"phases":658,"briefSummary":659,"conditions":660,"keywords":665,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":306},"100606226","phase-1-a-study-of-gi-108-an-anti-cd73-igg4-fc-il-2v-bispecific-fusion-protein-as-monotherapy-in-patients-with-advanced-or-metastatic-solid-tumors-100606226","NCT07172802","A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","An Open-label, Multicenter, Dose Escalation and Expansion Phase 1\u002F2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as a Single Agent in Patients With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatoryguidelines) at the time of screening.\n* Has adequate organ and marrow function as defined in protocol.\n* Measurable disease as per RECIST v1.1.\n* ECOG performance status 0-1.\n* Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy,other prior systemic anti-cancer therapy, or surgery must have resolved to Grade≤1, except alopecia and Grade 2 peripheral neuropathy.\n* HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection\u002Fdisease as defined in protocol.\n\nKey Exclusion Criteria:\n\n* Has known active CNS metastases and\u002For carcinomatous meningitis. An active second malignancy.\n* Has active or a known history of Hepatitis B or known active Hepatitis C virus infection.\n* Has active tuberculosis or has a known history of active tuberculosis. Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration.\n* History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years.\n* Previous immunotherapies related to mode of action of GI-102. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroidtherapy or any other form of immunosuppressive medications within 2 weeksprior to Cycle 1 Day 1.",{"count":657,"type":21},76,[80,24],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors",[661,662,111,663,664,27],"Advanced Solid Tumor","Metastatic Solid Tumor","Head and Neck (HNSCC)","Pancreatic Cancer",[666],"GI-108",{"date":668,"type":34},"2025-09-15",{"date":670,"type":34},"2025-04-22",{"date":672,"type":21},"2027-09",{"name":674,"class":41},"GI Innovation, Inc.",{"id":676,"slug":677,"hasResults":12,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":4,"eligibilityCriteria":681,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":391,"enrollmentInfo":682,"targetDuration":4,"studyType":22,"phases":684,"briefSummary":685,"conditions":686,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":687,"lastUpdatePostDateStruct":688,"startDateStruct":690,"completionDateStruct":692,"leadSponsor":694,"locationsCount":42},"100605661","phase-3-a-comparison-of-vorolanib-tablets-combined-with-everolimus-versus-sunitinib-in-patients-with-advanced-renal-cell-carcinoma-who-have-progressed-after-treatment-with-immunotherapy-monotherapy-or-in-combination-with-tki-100605661","NCT07165418","A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI","A Multicenter, Randomized Controlled Study Comparing Vorolanib Tablets Plus Everolimus With Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed on Immunotherapy Monotherapy or in Combination With TKI","Inclusion Criteria:\n\n1. Pathologically confirmed renal clear cell carcinoma (histological or cytological);\n2. Subjects who have failed prior treatment with a single anti-PD-1\u002FPD-L1 agent or a combination of anti-PD-1\u002FPD-L1 and anti-VEGFR TKI;\n3. Age 18 to 80 years;\n4. Estimated survival exceeding 12 weeks;\n5. KPS score ≥70;\n6. At least one measurable lesion per RECIST 1.1 criteria, which has not received prior radiation therapy;\n7. Adequate organ function levels;\n8. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization; all enrolled subjects (male or female) must use effective barrier contraception throughout treatment and for 4 weeks post-treatment;\n9. Subjects must be capable of understanding and voluntarily signing the informed consent form, which must be signed prior to any trial procedures.\n\nExclusion Criteria:\n\n1. Patients who have received one or more prior systemic anticancer treatment regimens for clear cell renal cell carcinoma;\n2. Patients who have not previously received immunosuppressive therapy for advanced renal cell carcinoma;\n3. Subjects currently undergoing anticancer therapy (excluding local radiotherapy for bone metastases);\n4. Subjects with known hypersensitivity to similar drugs;\n5. Subjects with active infectious diseases;\n6. Any uncontrolled clinical condition;\n7. Undergone major surgery within 4 weeks prior to enrollment;\n8. History of significant psychiatric disorders that may impair understanding of informed consent or compliance with the study protocol;\n9. Any condition affecting the subject's ability to swallow medication;\n10. Pregnant or lactating women;\n11. Subjects with severe pulmonary disease, asthma, or COPD history, with pulmonary function tests indicating moderate or greater impairment;\n12. Any other factors deemed by the investigator to make the subject unsuitable for participation in the study.",{"count":683,"type":21},116,[54],"This study is a multicenter, open-label, randomized controlled trial that enrolled 116 patients with advanced or metastatic renal cell carcinoma who had failed first-line treatment with PD-1\u002FPD-L1 monotherapy or VEGFR TKI combined with PD-1\u002FPD-L1 therapy. Patients were randomly assigned in a 1:1 ratio to receive either the experimental group treatment with vorolanib tablets combined with everolimus or the control group treatment with sunitinib as second-line therapy until disease progression. The study aimed to evaluate the efficacy and safety of vorolanib tablets combined with everolimus as second-line therapy for renal cell carcinoma patients.",[27],"2025-09-02",{"date":689,"type":34},"2025-09-10",{"date":691,"type":21},"2025-09-25",{"date":693,"type":21},"2029-12-30",{"name":695,"class":67},"Peking University Cancer Hospital & Institute"]